Biomaxima Sa · GPW:BMX
Biomaxima Sa — Q1 2025 Earnings Presentation
22 slides from Biomaxima Sa's earnings presentation, Jun 2, 2025
Slide 1: First Quarter 2025 Results and Discussion of 2024 Performance, Strategy Execution
First Quarter 2025 Results and Discussion of 2024 Performance, StrategyExecution 02.06.2025r. 1
Slide 2: Disclaimer
Disclaimer This presentation is for informational purposes only and aims to provide selected information regarding the BioMaxima S.A. Capital Group (BioMaxima S.A.). It does not constitute an advertisement or an offer of securities for public trading. The information contained in this presentation i
Slide 3: Results Q1 2025 vs. Q1 2024 (PLN thousands)
RESULTS ● Q1 2025 RESULTS Results Q1 2025 vs. Q1 2024 (PLN thousands) 925 15 281 Strong revenue growth in Q1 2025 compared to the 11 532 same period of the previous year. 281 Improved operating profitability – significant increase in the EBITDA margin. 2024 2025 2024 2025 Stable operating costs desp
Slide 4: First Quarter 2025 Results (PLN thousands)
RESULTS ● Q1 2025 RESULTS First Quarter 2025 Results (PLN thousands) 1 q 2025 1 q 2024 Variation (%) Sales Revenue 15 281 11 532 +32% Operating Profit 925 281 +229% EBITDA 1 822 1091 +67% Net Profit 589 250 +135% Fixed Assets 50 357 50 834 -1% Inventory 14 208 12 670 +12% Receivables 14 343 10 104 +
Slide 5: Sales dynamics of selected product categories, in-house production
RESULTS ● Q1 2025 RESULTS Sales dynamics of selected product categories, in-house production (PLN thousands) + 24,14% 1Q2024 1Q2025 Biochemistry Rapid Tests Antibiotic Discs Media on Plates Media in Tubes and Bottles Revenues are increasing in the segments where the Company invested in infrastructur
Slide 6: Domestic vs. Export Sales Dynamics 1Q2025 vs. 1Q2024
RESULTS ● RESULTS 1Q2025 Domestic vs. Export Sales Dynamics 1Q2025 vs. 1Q2024 (PLN thousands) +32,51% Expansion into new markets. 15 281 11 532 Export sales are growing, with exports accounting for 34% of total sales at the end of Q1 2025. 1Q2024 1Q2025 Poland UE Export 6
Slide 7: Sales volume dynamics of products where production capacity increased in 2022
RESULTS ● Q1 2025 RESULTS Sales volume dynamics of products where production capacity increased in 2022. 160% 150% • Cumulative sales volume growth over 12 140% months – from December 2022 to March 2025. Sales in 2022 = 100%. 130% 120% • In 2022–2023, production capacity was expanded for microbiolog
Slide 8: Financial Results 2024 vs. 2023 (PLN thousands)
RESULTS ● 2024 RESULTS Financial Results 2024 vs. 2023 (PLN thousands) 1308 52 851 46 786 14 752 12 467 728 2023 2024 2023 2024 2023 2024 Sales Revenue Operating Profit Export Sales 50 950 50 897 4 671 Total revenue growth of 12.96 3 216 EBITDA growth of 45% 2023 2024 2023 2024 Export revenue increa
Slide 9: Financial Results 2024 vs. 2023 (PLN thousands)
RESULTS ● 2024 RESULTS Financial Results 2024 vs. 2023 (PLN thousands) 2024 2023 Sales Revenue 52 851 46 786 Operating Profit 1 308 728 EBITDA 4 671 3 216 Net Profit 535 586 Fixed Assets 50 897 50 950 Inventory 13 517 12 721 Receivables 11 007 8 559 Equity 47 326 46 974 Non-current Liabilities 11 87
Slide 10: Public Tenders (domestic)
RESULTS ● 2024 RESULTS Public Tenders (domestic) Effectiveness in tenders (%) Total Won 65,93% 65,09% 53,18% 14,1 mln PLN 52,66% 53,22% 49,97% 11,5 mln PLN • 2023 – rapid tests Effectiveness 49.97% • 2024 – rapid tests Effectiveness 53.18% • Q1–Q4 2025 – rapid tests Effectiveness 65.93% Total Rapid
Slide 11: Sales Dynamics Domestic – Export 2024 (PLN thousands)
RESULTS ● 2024 RESULTS Sales Dynamics Domestic – Export 2024 (PLN thousands) CAGR 11,9% 52 851 44 538 46 308 Export sales continue to show long- 30 465 32 637 term upward trend. 30 068 The share of exports in total sales exceeding 35% at the end of 2024 2019 2020 2021 2022 2023 2024 (31% in 2022 and
Slide 12: Strategy Implementation
STRATEGY ● STRATEGY IMPLEMENTATION Strategy Implementation Strategy Implementation within 3 years from the launch of the completed investment MICROBIOLOGY 2020 Market: USD 15 billion (e)CAGR: 6.5% (e) (2020–2025)) COMPETITIVE REVENUE AST ADVANTAGES: Disc Diffusion and CAGR: 5.5% (2020–2025) (additio
Slide 13: Total Investments 2012-2023
TOTAL 2012-2023 Investments PLN 61 932 837 6000 m²
Slide 14: Sales Dynamics of Selected Product Categories, Own Production
RESULTS ● OPERATING AND FINANCIAL DATA Sales Dynamics of Selected Product Categories, Own Production (PLN thousands) 20654 2.473 16992 + 12 % 14937 + 9% 2.040 + 28% 12021 +1% + 22% 9589 + 11 % + 16% Data for 2020–2022 7173 + 101 % excluding + 43% + 63% COVID test sales - 8% + 15% + 139% + 46% - 2% +
Slide 15: Efficient Expansion of Export Markets (PLN thousands)
RESULTS ● OPERATING AND FINANCIAL DATA Efficient Expansion of Export Markets (PLN thousands) Trade Fair Expenses 14.888 (2018–2024) (PLN 3,275k) 12.415 2.473 11.022 1.393 7.929 2.040 7.924 8.982 7.426 1.556 Own Funds 6.959 965 PLN 1.442k Grant Funding PLN 1,833k 2018 2019 2020 2021 2022 2023 2024 Da
Slide 16: Investments generate economies of scale through increased productivity
RESULTS ● OPERATING AND FINANCIAL DATA Investments generate economies of scale through increased productivity, helping to offset the inflationary effects of 2023–2024 PLN 420k / 3,2% per employee PLN 407k / Revenue per employee: per employee 2023: PLN 46.8 million for 115 employees 2024: PLN 52.9 mi
Slide 17: Competitive Landscape
IN VITRO DIAGNOSTICS ● MARKET TRENDS Competitive Landscape Including Central Technology Europe Poland Europe MIC (AST) 3 0 0 Antibiotic Discs (AST) 5 1 0 Culture Media Supplements 10 2 0 Microbiological Culture 30 5 1 Media Rapid Tests 29 5 0 Source: own estimates, 2024 17
Slide 18: AST (Antibiotic Susceptibility Testing) - antibiotic discs and MIC tests
DEVELOPMENT ● PRODUCTION IMPLEMENTATION AST (Antibiotic Susceptibility Testing) - antibiotic discs and MIC tests • In 2024, the AST market grew to 4.02 billion USD compared to 3.81 billion USD in 2023 • Expected growth to 5.67 billion USD in 2030 with a CAGR of 5.83% 18
Slide 19: Operating in large, high-growth markets
IN VITRO DIAGNOSTICS ● MARKET TRENDS Operating in large, high- growth markets CAGR 4 % USD 6,7 BLN USD 8,9 BLN Microbiology media 2023 2030 CAGR 5,83% Antibiotic Susceptibility Testing USD 3,81 USD 5,67 (AST) BLN BLN 2023 2030 4 Source: Markets and Markets, 2024 19
Slide 20: High entry barriers for new producers
IN VITRO DIAGNOSTICS ● MARKET TRENDS High entry barriers for new producers: high costs of human capital development, Power of buyers: technological barriers: lack of availability of ready-to-use production equipment, the Local supplier oligopoly. Sensitivity to customer requires a wide range of prod
Slide 21: Anchoring in the microbiology market acts as a barrier to entry
IN VITRO DIAGNOSTICS ● MARKET TRENDS Anchoring in the microbiology market acts as a barrier to entry. Regulations constitute a capital-regulatory barrier: the entry of a new player requires years and significant investment. The infrastructure is tailor-made – for a new player, the technological thre
Slide 22: BIOMAXIMA joint-stock Company contact details
BIOMAXIMA joint-stock Company [email protected] CUSTOMER SERVICE OFFICE [email protected] +48 81 745 51 40 Our website: BIOMAXIMA.COM BIOMAXIMA S.A. ul. Vetterów 5, 20-277 Lublin